Emily Henderson

Senior Editor

Forensic Science, B.Sc.

Forensic Science, Analytical Chemistry

During her time at AZoNetwork, Emily has interviewed over 300 leading experts in all areas of science and healthcare including the World Health Organization and the United Nations. She loves being at the forefront of exciting new research and sharing science stories with thought leaders all over the world.

Emily graduated with a 2:1 in Forensic Science from Keele University and then completed a PGCE in Chemistry.

In Emily's spare time she enjoys watching true crime documentaries and reading books. She also loves the outdoors, enjoying long walks and discovering new places. She goes camping monthly and recently climbed Ben Nevis.

In the future, Emily wants to have travelled all over the world, learning about new cultures. She has an extensive bucket list and is keen for new adventures!

See less

Articles from Emily

The impact of COVID-19 on dialysis patients

In this interview, News-Medical speaks to Professor Simon Davies and Dr. Raymond Vanholder about the impact of COVID-19 on kidney dialysis patients.

1 Jul 2021

Achieving gender equality within global health

News-Medical spoke to Dr. Claire Bayntun about her incredible career in global health, and how we can achieve gender equality within healthcare settings.

28 Jun 2021

A World First: sequencing polyclonal antibodies using only proteomics

News-Medical speaks to Bin Ma, President of Rapid Novor, about their latest research that sequenced polyclonal antibodies using only proteomics.

21 Jun 2021

The importance of social distancing for COVID-19 recovery in the US

News-Medical spoke to researchers from Reykjavík University about their research that looked at the importance of social distancing in COVID-19 recovery.

21 Jun 2021

Does the number of siblings you have affect your health?

News-Medical spoke to Professor Peter M Nilsson about cardiovascular disease risk and whether this is affected by the number of siblings you have.

15 Jun 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021